Announced Date: 2025-11-08 (November 08, 2025)
Licensor: SanegeneBio (China)
Licensee: Eli Lilly （US）
.
Scope of Collaboration:
RNAi research for metabolic disease targets
Collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio’s proprietary tissue selective delivery technology, LEAD™ (Ligand and Enhancer Assisted Delivery).
.
SanegeneBio will be responsible for discovery and identification of the optimized LEAD™-based RNAi molecule for each program, while Lilly will be responsible for the subsequent IND-enabling studies, clinical development and commercialization.
.
Deal Detail:
SanegeneBio will receive an upfront payment and equity investment and will be eligible to receive near-term milestone payments.
SanegeneBio will also be eligible to receive up to $1.2 billion in discovery, development, regulatory, and commercial milestone payments, as well as tiered royalties on future product sales.
.
Link:
SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly (prnewswire.com)
.
Note:
Chinese Name of SanegeneBio, 圣因生物
